Corresponding author:, Prof. Man-Fung Yuen Email address: <u>mfyuen@hkucc.hku.hk</u>

#### Author affiliations:

Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong Assembly Biosciences, Inc

Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China

# Persistently detectable serum HBV DNA and pgRNA is associated with subsequent hepatocellular carcinoma development in chronic hepatitis B patients receiving chronic NRTI treatment

Lung-Yi Mak, Qi Huang, Danny Ka-Ho Wong, Ka-Shing Cheung, Kwan-Lung Ko, Ran Yan, James Fung, WK Seto, Man-Fung Yuen

#### **Background and Aim**

In patients with chronic hepatitis B (CHB) infection, the risk of liver-related complications, in particular hepatocellular carcinoma (HCC), is not completely eliminated. We aimed to assess whether residual hepatitis B virus (HBV) viraemia is associated with HCC development.

	HCC (N=52)	Non-HCC (N=52)	P value
Age	61.2 (56.9 – 66.6)	61.2 (56.9 – 66.5)	1.00
Gender (male)	42 (80.8%)	42 (80.8%)	1.00
Duration on NRTI till HCC diagnosis or last FU (months)	44.0 (26.1 – 57.1)	46.8 (32.1 – 65.7)	0.259
Presence of cirrhosis at baseline	20 (38.5%)	20 (38.5%)	1.00



# Methods

- Case-control study
- 104 CHB patients [52 HCC and 52 non-HCC (matched with age, gender, cirrhosis and treatment duration)]
- On ≥3 years entecavir (ETV)
- With unquantifiable HBV DNA by Cobas Taqman assay v2.0 (Roche Diagnostics; lower limit of quantification [LLOQ] 20 IU/mL)
- Serial sera within 1, 1-2, and >2 years prior to HCC diagnosis or last follow-up (LFU)
  Detection of HBV DNA and pre-genomic (pg) RNA using a highly sensitive semi-quantitative RT-PCR assay with lower limit of detection (LLOD) of 10 IU/mL and LLOQ of 51.5 IU/mL respectively

Gerum HBV DNA level at >2 Years before HCC (log <sub>10</sub> IU/mL)	1.71 (0.7 – 3.71)	1.73 (0 – 1.73)	0.028
Ferum HBV pgRNA level at >2 rears before HCC (log <sub>10</sub> IU/mL)	2.5 (1.71 – 4.47)	1.73 (1.73 – 2.44)	0.005
Gerum qHBsAg level at >2 years Defore HCC (log <sub>10</sub> mIU/mL)	2.9 (2.5 – 3.2)	2.7 (2.4 – 3)	0.167



### Results

Among the 104 patients,

- 80.8% male, median age 61.2 years old, 38.5% cirrhosis, median duration of ETV 45.5 months
- 38.5% and 9.6% HCC patients had undetectable serum DNA and pgRNA,





respectively; compared to 65.4% and 36.5% in non-HCC patients; P=0.005 & 0.001 respectively at the time of HCC diagnosis/ LFU (Figures 1& 2)

- No significant differences were observed for qHBsAg levels between HCC and non-HCC patients over 3 time points
- Detectable viral nucleic acids (HBV DNA and/or pgRNA) was associated with a higher 2-year risk of HCC development (HR 2.604, 95%CI 1.151-5.891; P=0.022)
  Poorly-differentiated HCC or presence of lymphovascular permeation tended to have lower serum pgRNA around the time of HCC diagnosis

# Conclusion

More than 50% CHB patients on ETV with HBV DNA <LLOQ by standard assay had persistent viraemia as determined by a more sensitive assay. Detectable HBV DNA and/or pgRNA was associated with HCC development. More potent viral suppression is required to further reduce the risk of HCC.